{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:49:53Z","timestamp":1791456593933,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12871-y","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:55:55Z","timestamp":1791453355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuclear factor \u03baB signalling in breast cancer: mechanisms, crosstalk and therapeutic targeting"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-5640","authenticated-orcid":false,"given":"Bavanilatha","family":"Muthiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1375-1524","authenticated-orcid":false,"given":"Raghul Rajah","family":"Santha Moorthi Rajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9863-6210","authenticated-orcid":false,"given":"Aakash Sumesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2796-0741","authenticated-orcid":false,"given":"Sudha","family":"Srikesavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-1672","authenticated-orcid":false,"given":"Valli Nachiyar","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaviya","family":"Priya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"19","key":"12871_CR1","doi-asserted-by":"publisher","first-page":"9967","DOI":"10.1093\/nar\/gkz739","volume":"47","author":"MC Mulero","year":"2019","unstructured":"Mulero MC, Wang VY-F, Huxford T, Ghosh G (2019) Genome reading by the NF-\u03baB transcription factors. Nucleic Acids Res 47(19):9967\u20139989. https:\/\/doi.org\/10.1093\/nar\/gkz739","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"12871_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.gendis.2020.06.005","volume":"8","author":"MR Zinatizadeh","year":"2021","unstructured":"Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi K, Jalali P, S. A., Miri SR (2021) The nuclear factor kappa B (NF-\u03baB) signaling in cancer development and immune diseases. Genes Dis 8(3):287\u2013297. https:\/\/doi.org\/10.1016\/j.gendis.2020.06.005","journal-title":"Genes Dis"},{"issue":"6","key":"12871_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/ph16060783","volume":"16","author":"X Wu","year":"2023","unstructured":"Wu X, Sun L, Xu F (2023) NF-\u03baB in cell deaths, therapeutic resistance and nanotherapy of tumors: Recent advances. Pharmaceuticals 16(6):783. https:\/\/doi.org\/10.3390\/ph16060783","journal-title":"Pharmaceuticals"},{"key":"12871_CR4","doi-asserted-by":"publisher","first-page":"122684","DOI":"10.1016\/j.lfs.2024.122684","volume":"348","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Lin M, Zeng C, Zhang J (2024) NF-\u03baB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges. Life Sci 348:122684. https:\/\/doi.org\/10.1016\/j.lfs.2024.122684","journal-title":"Life Sci"},{"issue":"10","key":"12871_CR5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/cells11101673","volume":"11","author":"S Diep","year":"2022","unstructured":"Diep S, Maddukuri M, Yamauchi S, Geshow G, Delk NA (2022) Interleukin-1 and nuclear factor kappa B signaling promote breast cancer progression and treatment resistance. Cells 11(10):1673. https:\/\/doi.org\/10.3390\/cells11101673","journal-title":"Cells"},{"issue":"27","key":"12871_CR6","doi-asserted-by":"publisher","first-page":"10137","DOI":"10.1073\/pnas.0403621101","volume":"101","author":"DK Biswas","year":"2004","unstructured":"Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101(27):10137\u201310142. https:\/\/doi.org\/10.1073\/pnas.0403621101","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"12871_CR7","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/cas.15734","volume":"114","author":"Y Takeuchi","year":"2023","unstructured":"Takeuchi Y, Gotoh N (2023) Inflammatory cytokine-enriched microenvironment plays key roles in the development of breast cancers. Cancer Sci 114(5):1792\u20131799. https:\/\/doi.org\/10.1111\/cas.15734","journal-title":"Cancer Sci"},{"issue":"18","key":"12871_CR8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2217\/pgs-2017-0044","volume":"18","author":"YH Park","year":"2017","unstructured":"Park YH (2017) The nuclear factor-kappa B pathway and response to treatment in breast cancer. Pharmacogenomics 18(18):1697\u20131709. https:\/\/doi.org\/10.2217\/pgs-2017-0044","journal-title":"Pharmacogenomics"},{"issue":"1","key":"12871_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.molcel.2005.03.006","volume":"18","author":"K-J Park","year":"2005","unstructured":"Park K-J, Krishnan V, O\u2019Malley BW, Yamamoto Y, Gaynor RB (2005) Formation of an IKK\u03b1-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18(1):71\u201382. https:\/\/doi.org\/10.1016\/j.molcel.2005.03.006","journal-title":"Mol Cell"},{"key":"12871_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","volume":"18","author":"M Karin","year":"2000","unstructured":"Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: The control of NF-\u03baB activity. Annu Rev Immunol 18:621\u2013663. https:\/\/doi.org\/10.1146\/annurev.immunol.18.1.621","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"12871_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2006.12.033","volume":"128","author":"S Basak","year":"2007","unstructured":"Basak S, Kim H, Kearns JD, Tergaonkar V, O\u2019Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A (2007) A fourth I\u03baB protein within the NF-\u03baB signaling module. Cell 128(2):369\u2013381. https:\/\/doi.org\/10.1016\/j.cell.2006.12.033","journal-title":"Cell"},{"issue":"2","key":"12871_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molcel.2006.03.026","volume":"22","author":"C-K Ea","year":"2006","unstructured":"Ea C-K, Deng L, Xia Z-P, Pineda G, Chen ZJ (2006) Activation of IKK by TNF\u03b1 requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 22(2):245\u2013257. https:\/\/doi.org\/10.1016\/j.molcel.2006.03.026","journal-title":"Mol Cell"},{"issue":"9","key":"12871_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"S-C Sun","year":"2017","unstructured":"Sun S-C (2017) The non-canonical NF-\u03baB pathway in immunity and inflammation. Nat Rev Immunol 17(9):545\u2013558. https:\/\/doi.org\/10.1038\/nri.2017.52","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"12871_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/cr.2010.161","volume":"21","author":"VF-S Shih","year":"2011","unstructured":"Shih VF-S, Tsui R, Caldwell A, Hoffmann A (2011) A single NF\u03baB system for both canonical and non-canonical signaling. Cell Res 21(1):86\u2013102. https:\/\/doi.org\/10.1038\/cr.2010.161","journal-title":"Cell Res"},{"issue":"7","key":"12871_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.tcb.2012.04.001","volume":"22","author":"K Iwai","year":"2012","unstructured":"Iwai K (2012) Diverse ubiquitin signaling in NF-\u03baB activation. Trends Cell Biol 22(7):355\u2013364. https:\/\/doi.org\/10.1016\/j.tcb.2012.04.001","journal-title":"Trends Cell Biol"},{"issue":"18","key":"12871_CR16","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/emboj.2011.264","volume":"30","author":"J Niu","year":"2011","unstructured":"Niu J, Shi Y, Iwai K, Wu Z-H (2011) LUBAC regulates NF-\u03baB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J 30(18):3741\u20133753. https:\/\/doi.org\/10.1038\/emboj.2011.264","journal-title":"EMBO J"},{"issue":"1","key":"12871_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/jcb.20789","volume":"98","author":"NR Monks","year":"2006","unstructured":"Monks NR, Pardee AB (2006) Targeting the NF-kappa B pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs. J Cell Biochem 98(1):221\u2013233. https:\/\/doi.org\/10.1002\/jcb.20789","journal-title":"J Cell Biochem"},{"issue":"12","key":"12871_CR18","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/ni.2446","volume":"13","author":"VF-S Shih","year":"2012","unstructured":"Shih VF-S, Davis-Turak J, Macal M, Huang JQ, Ponomarenko J, Kearns JD, Yu T, Fagerlund R, Asagiri M, Zuniga EI, Hoffmann A (2012) Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-\u03baB pathways. Nat Immunol 13(12):1162\u20131170. https:\/\/doi.org\/10.1038\/ni.2446","journal-title":"Nat Immunol"},{"key":"12871_CR19","doi-asserted-by":"publisher","first-page":"123059","DOI":"10.1016\/j.lfs.2024.123059","volume":"357","author":"V De Paolis","year":"2024","unstructured":"De Paolis V, Troisi V, Bordin A, Pagano F, Caputo V, Parisi C (2024) Unconventional p65\/p52 NF-\u03baB module regulates key tumor microenvironment-related genes in breast tumor-associated macrophages (TAMs). Life Sci 357:123059. https:\/\/doi.org\/10.1016\/j.lfs.2024.123059","journal-title":"Life Sci"},{"key":"12871_CR20","doi-asserted-by":"publisher","first-page":"e86258","DOI":"10.7554\/eLife.86258","volume":"12","author":"W Pan","year":"2023","unstructured":"Pan W, Meshcheryakov VA, Li T, Wang Y, Ghosh G, Wang VY-F (2023) Structures of NF-\u03baB p52 homodimer-DNA complexes rationalize binding mechanisms and transcription activation. eLife 12:e86258. https:\/\/doi.org\/10.7554\/eLife.86258","journal-title":"eLife"},{"issue":"19","key":"12871_CR21","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.1021\/acsomega.1c01299","volume":"6","author":"T Raza","year":"2021","unstructured":"Raza T, Dhaka N, Joseph D, Dadhwal P, Kakita VMR, Atreya HS, Mukherjee SP (2021) Insights into the NF-\u03baB-DNA interaction through NMR spectroscopy. ACS Omega 6(19):12877\u201312886. https:\/\/doi.org\/10.1021\/acsomega.1c01299","journal-title":"ACS Omega"},{"issue":"6","key":"12871_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12032-021-01509-7","volume":"38","author":"K Mehdizadeh","year":"2021","unstructured":"Mehdizadeh K, Ataei F, Hosseinkhani S (2021) Treating MCF7 breast cancer cell with proteasome inhibitor bortezomib restores apoptotic factors and sensitizes cell to docetaxel. Med Oncol 38(6):64. https:\/\/doi.org\/10.1007\/s12032-021-01509-7","journal-title":"Med Oncol"},{"issue":"1","key":"12871_CR23","doi-asserted-by":"publisher","first-page":"e0169622","DOI":"10.1371\/journal.pone.0169622","volume":"12","author":"BRB Pires","year":"2017","unstructured":"Pires BRB, Mencalha AL, Ferreira GM, de Souza WF, Morgado-D\u00edaz JA, Maia AM, Abdelhay ES F. W (2017) NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS ONE 12(1):e0169622. https:\/\/doi.org\/10.1371\/journal.pone.0169622","journal-title":"PLoS ONE"},{"issue":"5","key":"12871_CR24","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1073\/pnas.0437939100","volume":"100","author":"E Voronov","year":"2003","unstructured":"Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100(5):2645\u20132650. https:\/\/doi.org\/10.1073\/pnas.0437939100","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"12871_CR25","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","volume":"25","author":"C Tulotta","year":"2019","unstructured":"Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, de Kruithof- M, Coleman RE, Brown JE, Holen I, Ottewell PD (2019) Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res 25(9):2769\u20132782. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2202","journal-title":"Clin Cancer Res"},{"key":"12871_CR26","doi-asserted-by":"publisher","first-page":"1457491","DOI":"10.3389\/fimmu.2024.1457491","volume":"15","author":"A Sami","year":"2024","unstructured":"Sami A, Raza A (2024) Reprogramming the tumor microenvironment\u2014macrophages emerge as key players in breast cancer immunotherapy. Front Immunol 15:1457491. https:\/\/doi.org\/10.3389\/fimmu.2024.1457491","journal-title":"Front Immunol"},{"issue":"6","key":"12871_CR27","doi-asserted-by":"publisher","first-page":"R369","DOI":"10.1530\/ERC-19-0087","volume":"26","author":"P Khongthong","year":"2019","unstructured":"Khongthong P, Roseweir AK, Edwards J (2019) The NF-\u03baB pathway and endocrine therapy resistance in breast cancer. Endocrine-related Cancer 26(6):R369\u2013R380. https:\/\/doi.org\/10.1530\/ERC-19-0087","journal-title":"Endocrine-related Cancer"},{"issue":"19","key":"12871_CR28","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1158\/0008-5472.CAN-23-1711","volume":"83","author":"F Hermida-Prado","year":"2023","unstructured":"Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, Garc\u00eda-Pedrero J, Ca\u00f1adas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA (2023) Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer Res 83(19):3284\u20133304. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1711","journal-title":"Cancer Res"},{"issue":"24","key":"12871_CR29","doi-asserted-by":"publisher","first-page":"e38508","DOI":"10.1097\/MD.0000000000038508","volume":"103","author":"L Pan","year":"2024","unstructured":"Pan L, Li J, Xu Q, Gao Z, Yang M, Wu X, Li X (2024) HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review. Medicine 103(24):e38508. https:\/\/doi.org\/10.1097\/MD.0000000000038508","journal-title":"Medicine"},{"issue":"1","key":"12871_CR30","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1038\/s41598-023-32321-0","volume":"13","author":"AS Bapat","year":"2023","unstructured":"Bapat AS, O\u2019Connor CH, Schwertfeger KL (2023) Targeting the NF-\u03baB pathway enhances responsiveness of mammary tumors to JAK inhibitors. Sci Rep 13(1):5349. https:\/\/doi.org\/10.1038\/s41598-023-32321-0","journal-title":"Sci Rep"},{"issue":"8","key":"12871_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, kConFab, Rohrbach K, Huang L-Y, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22(8):933\u2013939. https:\/\/doi.org\/10.1038\/nm.4118","journal-title":"Nat Med"},{"issue":"11","key":"12871_CR32","doi-asserted-by":"publisher","first-page":"e098846","DOI":"10.1136\/bmjopen-2025-098846","volume":"15","author":"L Li","year":"2025","unstructured":"Li L, Wang X, Li Y, Shen S, Xu Y, Zhou Y, Sun Q (2025) Prognostic value of RANK signalling in breast cancer: A systematic review and meta-analysis. BMJ Open 15(11):e098846. https:\/\/doi.org\/10.1136\/bmjopen-2025-098846","journal-title":"BMJ Open"},{"key":"12871_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y (2021) Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct Target Therapy 6:263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"12871_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.mce.2014.09.013","volume":"418","author":"J Frasor","year":"2015","unstructured":"Frasor J, El-Shennawy L, Stender JD, Kastrati I (2015) NF\u03baB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol 418(3):235\u2013239. https:\/\/doi.org\/10.1016\/j.mce.2014.09.013","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"12871_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/annonc\/mdm569","volume":"19","author":"P Schmid","year":"2008","unstructured":"Schmid P, K\u00fchnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, K\u00fcmmel S, Van de Velde H, Regierer A, Possinger K (2008) A phase I\/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and\/or anthracyclines. Ann Oncol 19(5):871\u2013876. https:\/\/doi.org\/10.1093\/annonc\/mdm569","journal-title":"Ann Oncol"},{"key":"12871_CR36","doi-asserted-by":"publisher","first-page":"16037","DOI":"10.1038\/npjbcancer.2016.37","volume":"2","author":"K Adelson","year":"2016","unstructured":"Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL (2016) Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York Cancer Consortium trial. NPJ Breast Cancer 2:16037. https:\/\/doi.org\/10.1038\/npjbcancer.2016.37","journal-title":"NPJ Breast Cancer"},{"issue":"23","key":"12871_CR37","doi-asserted-by":"publisher","first-page":"36936","DOI":"10.18632\/oncotarget.16294","volume":"8","author":"VL Battula","year":"2017","unstructured":"Battula VL, Nguyen K, Sun J, Pitner MK, Yuan B, Bartholomeusz C, Hail N, Andreeff M (2017) IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2\u2009+\u2009cancer stem cells. Oncotarget 8(23):36936\u201336949. https:\/\/doi.org\/10.18632\/oncotarget.16294","journal-title":"Oncotarget"},{"key":"12871_CR38","doi-asserted-by":"publisher","first-page":"109247","DOI":"10.1016\/j.bioorg.2025.109247","volume":"167","author":"X Huang","year":"2025","unstructured":"Huang X, Zong R, Zhu Y, Li R (2025) Targeting NF-\u03baB-inducing kinase (NIK) in the non-canonical pathway: Advances in the development of NIK inhibitors. Bioorg Chem 167:109247. https:\/\/doi.org\/10.1016\/j.bioorg.2025.109247","journal-title":"Bioorg Chem"},{"issue":"11","key":"12871_CR39","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3390\/ph18111764","volume":"18","author":"K Lukas","year":"2025","unstructured":"Lukas K, Nguyen J, Necas C, Dave K, Venketaraman V (2025) Targeting the NF-\u03baB pathway in cancer: Mechanisms, resistance, and therapeutic potential across tumor types. Pharmaceuticals 18(11):1764. https:\/\/doi.org\/10.3390\/ph18111764","journal-title":"Pharmaceuticals"},{"issue":"1","key":"12871_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, Kapse P, Gosavi SW, Kundu GC (2024) Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer 23(1):92. https:\/\/doi.org\/10.1186\/s12943-024-01990-4","journal-title":"Mol Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12871-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12871-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:55:56Z","timestamp":1791453356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12871-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12871"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12871-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest, financial or otherwise.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Literature was identified using combinations of the terms \u201cNF-\u03baB\u201d, \u201cbreast cancer\u201d, \u201ccanonical NF-\u03baB\u201d, \u201cnoncanonical NF-\u03baB\u201d, \u201cIKK\u201d, \u201cNIK\u201d, \u201cRANK\/RANKL\u201d, \u201cHER2\u201d, \u201ctriple-negative breast cancer\u201d, \u201cendocrine resistance\u201d, \u201ctherapy resistance\u201d, \u201cSMAC mimetics\u201d and related pathway terms. Priority was given to primary mechanistic studies, breast-cancer-specific translational studies, clinical studies and recent reviews, with backward and forward reference screening used to identify relevant foundational and emerging evidence. The literature was considered through 2025, while older primary studies were retained where they established observations or mechanisms that remain central to the field.","order":6,"name":"Ethics","label":"Literature search approach","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1687"}}